These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31930974)

  • 21. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
    Pockros PJ; Fuchs M; Freilich B; Schiff E; Kohli A; Lawitz EJ; Hellstern PA; Owens-Grillo J; Van Biene C; Shringarpure R; MacConell L; Shapiro D; Cohen DE
    Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging and future therapies for nonalcoholic steatohepatitis in adults.
    Mintziori G; Polyzos SA
    Expert Opin Pharmacother; 2016 Oct; 17(14):1937-46. PubMed ID: 27564402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies.
    Jahn D; Rau M; Wohlfahrt J; Hermanns HM; Geier A
    Dig Dis; 2016; 34(4):356-63. PubMed ID: 27170389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid.
    Wang K; Zhang Y; Wang G; Hao H; Wang H
    Med Res Rev; 2024 Mar; 44(2):568-586. PubMed ID: 37899676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
    Rotman Y; Sanyal AJ
    Gut; 2017 Jan; 66(1):180-190. PubMed ID: 27646933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging Therapies for Nonalcoholic Fatty Liver Disease.
    Hameed B; Terrault N
    Clin Liver Dis; 2016 May; 20(2):365-85. PubMed ID: 27063275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need.
    Guaraldi G; Maurice JB; Marzolini C; Monteith K; Milic J; Tsochatzis E; Bhagani S; Morse CG; Price JC; Ingiliz P; Lemoine M; Sebastiani G;
    Hepatology; 2020 May; 71(5):1831-1844. PubMed ID: 32052857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease.
    Fiorucci S; Biagioli M; Baldoni M; Ricci P; Sepe V; Zampella A; Distrutti E
    Expert Opin Drug Discov; 2021 Oct; 16(10):1193-1208. PubMed ID: 33849361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.
    Singh S; Khera R; Allen AM; Murad MH; Loomba R
    Hepatology; 2015 Nov; 62(5):1417-32. PubMed ID: 26189925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease.
    Zhang DY; Zhu L; Liu HN; Tseng YJ; Weng SQ; Liu TT; Dong L; Shen XZ
    Drug Des Devel Ther; 2019; 13():2249-2270. PubMed ID: 31308634
    [No Abstract]   [Full Text] [Related]  

  • 32. Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.
    Oh H; Jun DW; Saeed WK; Nguyen MH
    Clin Mol Hepatol; 2016 Sep; 22(3):327-335. PubMed ID: 27729634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The NASH drug dash.
    Chi KR
    Nat Rev Drug Discov; 2015 Jul; 14(7):447-8. PubMed ID: 26129791
    [No Abstract]   [Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease: another leap forward.
    Abdelmalek MF
    Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):85-86. PubMed ID: 33420415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Golabi P; Bush H; Younossi ZM
    Clin Liver Dis; 2017 Nov; 21(4):739-753. PubMed ID: 28987260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
    Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
    Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Starting the battle to control non-alcoholic steatohepatitis.
    Ratziu V
    Lancet; 2015 Mar; 385(9972):922-4. PubMed ID: 25468161
    [No Abstract]   [Full Text] [Related]  

  • 39. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis.
    Tølbøl KS; Stierstorfer B; Rippmann JF; Veidal SS; Rigbolt KTG; Schönberger T; Gillum MP; Hansen HH; Vrang N; Jelsing J; Feigh M; Broermann A
    Dig Dis Sci; 2019 May; 64(5):1238-1256. PubMed ID: 30511198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.